The rationale for combining afatinib with cetuximab in R/M HNSCC is based on preclinical studies showing that resistance to EGFR inhibition frequently arises through compensatory signaling mediated by other ErbB family members, particularly HER2 and HER3 [92]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.